Tag: test for breast cancer

Some Labs Performing ADLTs May See Increased Medicare Fees

MIXED IN THE BAD NEWS concerning the proposed Clinical Laboratory Fee Schedule for 2018, there is some good news regarding what the federal Centers for Medicare and Medicaid Services proposes to pay for certain advanced diagnostic tests.

After analyzing the proposed fee schedule, Quorum Consulting of San Francisco, reported, as other analysts have concluded, that CMS

View Article

UnitedHealthcare, BeaconLBS Respond with Statements

IN FLORIDA, BOTH CLINICAL LABS and physicians have expressed concerns UnitedHealthcare’s Laboratory presented in full on this page and the following page. about Benefit Management Program that formally becomes effective on October 1. From that date forward, physicians will be required to obtain advance notification or pre-authorization for 81 tests.

Following our request for comment from

View Article

Is Lab Industry Ready for Facebook and MySpace?

WHO COULD HAVE IMAGINED, JUST A FEW YEARS AGO, that social networking sites such as Facebook.com, MySpace.com, and YouTube.com would become a useful platform that allows clinical laboratories, pathology groups, and in vitro diagnostics (IVD) companies to engage in two-way conversations with patients and customers?

After all, in those days, the preponderance of active users of

View Article

Lab M&A Deals in June Show Market Direction

CEO SUMMARY: Despite a dismal economy, the month of June spawned two interesting merger/acquisition transactions in the lab testing industry. In one case, a blood brother gobbled up a specialty diagnostics company. In another transaction, two cross-town neighbors in Kansas City merged to form an enhanced specialty diagnostics laboratory company. The common theme behind both

View Article

Ventana & Cytyc Fall Short, Danaher Wins the Prize

WHEN Danaher Corporation’s high bid for Vision Systems Limited of Melbourne, Australia, was accepted last month, it appeared to be simply another acquisition by a large U.S. manufacturer. But, in fact, there are four reasons this transaction is significant to pathologists in the United States and worldwide.

If approved by Vision’s shareholders later this year, the

View Article